Skip to content
Research library

Clinical research overview

This library brings together peer-reviewed studies on Mesenchymal Stem Cells (MSCs) across a wide range of medical indications. Each study contributes to a deeper understanding of how MSCs support repair, regeneration, and immune balance in the body.
Crohn's disease Aging frailty Osteoarthritis
Acute respiratory disease syndrome Graft versus host disease (GvHD) Multiple sclerosis Liver cirrhosis Diabetes type II Diabetes type I Chronic low back pain Chronic obstructive pulmonary disease (COPD) Alzheimer's disease Rheumatoid arthritis

Liver cirrhosis

Mesenchymal Stem Cells (MSCs) are being studied in liver cirrhosis to explore whether their regenerative and immune-modulating properties may help support liver health. Current research evaluates biological signals such as anti-fibrotic activity and tissue repair. Liver cirrhosis is a progressive condition caused by long-term liver damage, often due to hepatitis, alcohol use, or metabolic disease. It leads to scarring, impaired function, and can progress to failure where transplantation remains the only curative option. Although findings are early, MSC investigations are expanding the scientific understanding of potential cell-based approaches in hepatology and regenerative medicine.

Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial

Ming Shi, et al.
MSC infusion was reported to improve liver function in patients with decompensated liver cirrhosis (DLC); however, whether the medication can improve outcome of these patients is poorly understood.
More
Read study

Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients

Ming Shi, et al.
Acute-on-chronic liver failure (ACLF) is a severe, life-threatening complication, and new and efficient therapeutic strategies for liver failure are urgently needed. Mesenchymal stem cell (MSC) transfusions have been shown to reverse fulminant hepatic failure in mice and to improve liver function in patients with end-stage liver diseases. No significant side effects were observed during the trial. The UC-MSC transfusions significantly increased the survival rates in ACLF patients; reduced the model for end-stage liver disease scores; increased serum albumin, cholinesterase, and prothrombin activity; and increased platelet counts.
More
Read study

Bone Marrow Mesenchymal Stem Cells in Acute-on-Chronic Liver Failure Grades 2 and 3: A Phase I-II Randomized Clinical Trial

Fernando Comunello Schacher, et al.
Acute-on-chronic liver failure (ACLF) is an acute liver decompensation in cirrhotic patients, which leads to organ failures and high short-term mortality. We aimed to evaluate the safety and initial efficacy of bone marrow mesenchymal stem cells (BM-MSC) in patients with ACLF Grades 2 and 3.
More
Read study

Third-party bone marrow-derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial

Federica Casiraghi, et al.
The incidence of serious and non-serious adverse events was similar in the two groups. Circulating Treg/memory Treg and tolerant NK subset of CD56bright NK cells increased slightly over baseline. Pretransplant MSC infusion in liver transplant recipients was safe and induced mild positive changes in immunoregulatory T and NK cells.
More
Read study

Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial

Pedram Kharaziha, et al.
Treatment was well tolerated by all patients. Liver function improved as verified by the Model for End-Stage Liver Disease score, which decreased from 17.9 to 10.7 and prothrombin complex from international normalized ratio 1.9 to 1.4. Serum creatinine decreased from 114 to 80 micromol/l. Serum albumin changed from 30 to 33 g/l and bilirubin from 46 to 41. No adverse effects were noted.
More
Read study

A Pilot Study of Mesenchymal Stem Cell Therapy for Acute Liver Allograft Rejection

Ming Shi, et al.
Four weeks after UC-MSC infusions, alanine aminotransferase levels had decreased markedly. Importantly, allograft histology was improved after administration of UC-MSCs. The percentage of regulatory T cells (Tregs) and the Treg/T helper 17 (Th17) cell ratio were significantly increased 4 weeks after infusions; in contrast, the percentage of Th17 cells showed a decreasing trend. In controls, the percentages of Tregs and Th17 cells and the Treg/Th17 ratio were statistically unchanged from the baseline measurements. Transforming growth factor beta 1 and prostaglandin E2 were increased significantly after UC-MSC infusions, there were no significant changes in controls.
More
Read study